Minerva Neuroscie (NERV)

$1.79 +0.03 (1.70%)
Market Cap 12.31M
Revenue (ttm) 0.00
Net Income (ttm) 1.44M
EPS (ttm) N/A
PE Ratio 9.26
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 324
Avg Vol 22,092
Day's Range N/A - N/A
Shares Out 6.99M
Stochastic %K 86%
Beta -0.09
Analysts Hold
Price Target $5.00

Latest News on NERV

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

Feb 25, 2025, 7:00 AM EST - 2 months ago

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

Nov 5, 2024, 7:30 AM EST - 6 months ago

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

May 1, 2024, 7:30 AM EDT - 1 year ago

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

US FDA declines to approve Minerva Neurosciences' schizophrenia drug

Feb 27, 2024, 8:14 AM EST - 1 year ago

US FDA declines to approve Minerva Neurosciences' schizophrenia drug

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

Feb 22, 2024, 7:00 AM EST - 1 year ago

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

Nov 7, 2023, 7:30 AM EST - 1 year ago

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

Minerva Neurosciences: There's Probably Time For One More Rally

Aug 23, 2023, 4:05 AM EDT - 1 year ago

Minerva Neurosciences: There's Probably Time For One More Rally

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

Aug 1, 2023, 7:30 AM EDT - 1 year ago

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

Jun 28, 2023, 8:30 AM EDT - 1 year ago

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead

May 19, 2023, 5:34 PM EDT - 2 years ago

Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead

Minerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Call Transcript

May 15, 2023, 11:26 AM EDT - 2 years ago

Minerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Call Transcript

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

May 15, 2023, 7:30 AM EDT - 2 years ago

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

May 10, 2023, 8:00 AM EDT - 2 years ago

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

May 8, 2023, 8:30 AM EDT - 2 years ago

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript

Mar 8, 2023, 11:31 AM EST - 2 years ago

Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript

Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

Mar 8, 2023, 7:30 AM EST - 2 years ago

Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Mar 1, 2023, 8:30 AM EST - 2 years ago

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript

Nov 9, 2022, 10:02 AM EST - 2 years ago

Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript

Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

Nov 9, 2022, 8:00 AM EST - 2 years ago

Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022

Nov 2, 2022, 8:30 AM EDT - 2 years ago

Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022

Minerva Neurosciences to request meeting with FDA about schizophrenia drug

Oct 17, 2022, 8:51 AM EDT - 2 years ago

Minerva Neurosciences to request meeting with FDA about schizophrenia drug

Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Oct 17, 2022, 8:30 AM EDT - 2 years ago

Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

Sep 9, 2022, 4:05 PM EDT - 2 years ago

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Aug 22, 2022, 8:00 AM EDT - 2 years ago

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

Aug 9, 2022, 8:00 AM EDT - 2 years ago

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

May 4, 2022, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Apr 7, 2022, 1:01 PM EDT - 3 years ago

Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Apr 7, 2022, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates

Mar 1, 2022, 7:30 AM EST - 3 years ago

Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates

Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Feb 28, 2022, 8:30 AM EST - 3 years ago

Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 2:11 PM EST - 3 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2021 Results - Earnings Call Transcript

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

Nov 8, 2021, 7:30 AM EST - 3 years ago

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

Nov 3, 2021, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

Nov 1, 2021, 8:30 AM EDT - 3 years ago

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

Minerva Neurosciences Announces Promotion of Geoff Race to President

Oct 11, 2021, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Announces Promotion of Geoff Race to President

Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations

Sep 30, 2021, 10:32 AM EDT - 3 years ago

Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

Sep 30, 2021, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2021 Results - Earnings Call Transcript

Aug 2, 2021, 12:19 PM EDT - 4 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2021 Results - Earnings Call Transcript

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

Aug 2, 2021, 7:30 AM EDT - 4 years ago

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021

Jul 26, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

Jun 10, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

May 28, 2021, 8:00 AM EDT - 4 years ago

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2021 Results - Earnings Call Transcript

May 12, 2021, 4:40 PM EDT - 4 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2021 Results - Earnings Call Transcript

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

May 12, 2021, 7:30 AM EDT - 4 years ago

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

May 11, 2021, 4:15 PM EDT - 4 years ago

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021

May 5, 2021, 5:10 PM EDT - 4 years ago

Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021

Minerva Neurosciences, Inc.'s (NERV) CEO Remy Luthringer on Q4 2020 Results - Earnings Call Transcript

Mar 8, 2021, 12:35 PM EST - 4 years ago

Minerva Neurosciences, Inc.'s (NERV) CEO Remy Luthringer on Q4 2020 Results - Earnings Call Transcript

Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates

Mar 8, 2021, 7:30 AM EST - 4 years ago

Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates

NERV DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Minerva Neurosciences, Inc. Investors to Secure Counsel Before Important Monday Deadline - NERV

Feb 8, 2021, 9:43 AM EST - 4 years ago

NERV DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Minerva Neurosciences, Inc. Investors to Secure Counsel Before Important Monday Deadline - NERV

NERV FINAL DEADLINE MONDAY: ROSEN, A RANKED AND LEADING FIRM, Encourages Minerva Neurosciences, Inc. Investors to Secure Counsel Before Important February 8 Deadline - NERV

Feb 5, 2021, 9:15 PM EST - 4 years ago

NERV FINAL DEADLINE MONDAY: ROSEN, A RANKED AND LEADING FIRM, Encourages Minerva Neurosciences, Inc. Investors to Secure Counsel Before Important February 8 Deadline - NERV